EM
Encore MedicalEncore Medical develops transcatheter septal occlusion devices to repair structural heart defects like patent foramen ovale (PFO).
2 Pulse stories
ST
Scribe TherapeuticsClinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.
5 Pulse stories
Total RaisedNot disclosed
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
2018
Eagan, Minnesota
HQ
Alameda, California
Public (EMI)
Status
Public (SCTX)
Encore Medical investors
No investors on record.
Scribe Therapeutics investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Encore Medical and Scribe Therapeutics.